Active	Status	Sponsor type	Region	Phase	Filter
8 Active 4 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Weiner, Howard
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) Jan 2024 - Dec 2024: Approval for myelofibrosis Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis Feb 2024 - Feb 2024: Completion of P2b trial for JIA Feb 2024 - Feb 2024: Exclusivity expiry in US	Active, not recruiting	3	430	Europe, Canada, US, RoW	Pelabresib, Ruxolitinib, Placebo	Constellation Pharmaceuticals	Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis	08/23	12/27
SL03-OHD-104, NCT05275439: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML	Active, not recruiting	1	160	Europe, Canada, US	SL-172154, Azacitidine, Venetoclax	Shattuck Labs, Inc.	Acute Myeloid Leukemia, Myelodysplastic Syndromes	11/24	11/24
Belen, Emanuel
No trials found
Wisor-Martinez, Sarah
No trials found
Fletcher, RC
No trials found